Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 1, 2026, 5:19 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 106 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Severe Functional Impairment Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

PK Study of Sotagliflozin in Subjects With Hepatic Impairment

NCT02471274
View directory record Official record
Conditions
Hepatic Impairment, Healthy
Interventions
sotagliflozin
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2015
U.S. locations
4
States / cities
Lakewood, Colorado • Miami, Florida • Orlando, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2016 · Synced Oct 1, 2026, 5:19 PM EDT
Completed Phase 1 Interventional

Sorafenib in Treating Patients With Metastatic or Unresectable Solid Tumors, Multiple Myeloma, or Non-Hodgkin's Lymphoma With or Without Impaired Liver or Kidney Function

NCT00118170
View directory record Official record
Conditions
Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Multiple Myeloma, Splenic Marginal Zone Lymphoma, Stage II Multiple Myeloma, Stage III Adult Burkitt Lymphoma, Stage III Adult Diffuse Large Cell Lymphoma, Stage III Adult Diffuse Mixed Cell Lymphoma, Stage III Adult Diffuse Small Cleaved Cell Lymphoma, Stage III Adult Immunoblastic Large Cell Lymphoma, Stage III Adult Lymphoblastic Lymphoma, Stage III Grade 1 Follicular Lymphoma, Stage III Grade 2 Follicular Lymphoma, Stage III Grade 3 Follicular Lymphoma, Stage III Mantle Cell Lymphoma, Stage III Marginal Zone Lymphoma, Stage III Multiple Myeloma, Stage III Small Lymphocytic Lymphoma, Stage IV Adult Burkitt Lymphoma, Stage IV Adult Diffuse Large Cell Lymphoma, Stage IV Adult Diffuse Mixed Cell Lymphoma, Stage IV Adult Diffuse Small Cleaved Cell Lymphoma, Stage IV Adult Immunoblastic Large Cell Lymphoma, Stage IV Adult Lymphoblastic Lymphoma, Stage IV Grade 1 Follicular Lymphoma, Stage IV Grade 2 Follicular Lymphoma, Stage IV Grade 3 Follicular Lymphoma, Stage IV Mantle Cell Lymphoma, Stage IV Marginal Zone Lymphoma, Stage IV Small Lymphocytic Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific, Waldenström Macroglobulinemia
Interventions
sorafenib tosylate, pharmacological study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 7, 2013 · Synced Oct 1, 2026, 5:19 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Lepodisiran (LY3819469) in Participants With Normal, Mild, Moderate, or Severe Liver Function

NCT06916078
View directory record Official record
Conditions
Liver Dysfunction, Healthy
Interventions
Lepodisiran
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
3
States / cities
Miami, Florida • Orlando, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 1, 2026, 5:19 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Mobocertinib Capsules in People With Severe Kidney Problems and People With Healthy Kidneys

NCT04056455
View directory record Official record
Conditions
Renal Impairment, Healthy Volunteers
Interventions
Mobocertinib
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 81 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
2
States / cities
Hialeah, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jan 8, 2024 · Synced Oct 1, 2026, 5:19 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic Study of Vorasidenib in Severe Hepatically Impaired and Matched-Control Participants

NCT07250633
View directory record Official record
Conditions
Severe Hepatic Impairment, Normal Hepatic Function
Interventions
Vorasidenib 20mg
Drug
Lead sponsor
Institut de Recherches Internationales Servier (I.R.I.S.)
Industry
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
3
States / cities
Chandler, Arizona • Orlando, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Oct 1, 2026, 5:19 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Evaluate Pharmacokinetics (PK) and Safety of Oral Mobocertinib in Participants With Moderate or Severe Hepatic Impairment (HI) and Normal Hepatic Function

NCT04056468
View directory record Official record
Conditions
Hepatic Impairment, Healthy Volunteers
Interventions
Mobocertinib
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 79 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
2
States / cities
Hialeah, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Nov 3, 2023 · Synced Oct 1, 2026, 5:19 PM EDT
Recruiting No phase listed Observational

Identifying Cerebral Hemodynamic Patterns in Mood Disorders and Mild Cognitive Impairment: A Functional Near-Infrared Spectroscopy (fNIRS) Study

NCT06897670
View directory record Official record
Conditions
Major Depressive Disorder, Bipolar Disorder, Mild Cognitive Impairment
Interventions
Observational assessment using functional near-infrared spectroscopy (fNIRS), a noninvasive, portable brain imaging tool that measures changes in brain blood flow and oxygen levels.
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
200 participants
Timeline
2025 – 2028
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Oct 1, 2026, 5:19 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Pharmacokinetics of VI-0521 Subjects With Renal Impairment

NCT00768404
View directory record Official record
Conditions
Renal Impairment
Interventions
Topirmate and Phentermine
Drug
Lead sponsor
VIVUS LLC
Industry
Eligibility
19 Years to 75 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
4
States / cities
Anaheim, California • Miami, Florida • Orlando, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2009 · Synced Oct 1, 2026, 5:19 PM EDT
Completed Phase 2 Interventional Results available

Effect of Power Wheelchairs on the Development and Function of Young Children With Severe Physical Disabilities

NCT01115998
View directory record Official record
Conditions
Cerebral Palsy, Child, Preschool
Interventions
Power wheelchair, No power wheelchairs
Other
Lead sponsor
University of Oklahoma
Other
Eligibility
14 Months to 30 Months
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Dec 5, 2016 · Synced Oct 1, 2026, 5:19 PM EDT
Completed Phase 4 Interventional Results available

Effectiveness of Methylphenidate in Improving Cognition and Function in Older Adults With Depression

NCT00602290
View directory record Official record
Conditions
Depression
Interventions
Citalopram, Methylphenidate (MPH), Placebo
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
60 Years and older
Enrollment
181 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 11, 2018 · Synced Oct 1, 2026, 5:19 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Drug Levels, Safety, and Tolerability of BMS-986036 in Participants With Normal Liver Function and Participants With Moderate and Severe Liver Impairment

NCT04634149
View directory record Official record
Conditions
Moderate Liver Impairment, Severe Liver Impairment
Interventions
BMS-986036
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
21 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
3
States / cities
Miami, Florida • Orlando, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 16, 2022 · Synced Oct 1, 2026, 5:19 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Pharmacokinetics and Safety of Remibrutinib in Participants With Severe Renal Impairment Compared to Matched Healthy Participants.

NCT07032272
View directory record Official record
Conditions
Autoimmune and Chronic Inflammatory Diseases
Interventions
remibrutinib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
4
States / cities
Miami, Florida • Miami Lakes, Florida • Orlando, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 1, 2026, 5:19 PM EDT
Completed Phase 1 Interventional

Open Label Pharmacokinetic Study of SAR302503 in Subjects With Renal Impairment

NCT01763190
View directory record Official record
Conditions
Renal Impairment
Interventions
SAR302503
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 79 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
3
States / cities
Orlando, Florida • Saint Paul, Minnesota • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 5, 2025 · Synced Oct 1, 2026, 5:19 PM EDT
Active, not recruiting Phase 2 Interventional

Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function

NCT06004661
View directory record Official record
Conditions
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Interventions
AAA617, 68Ga-PSMA-11
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years · Male only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 1, 2026, 5:19 PM EDT
Completed Phase 4 Interventional Results available

Pradaxa Study in Non-valvular Atrial Fibrillation Patients With Severely Impaired Renal Function

NCT01896297
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Pradaxa, dabigatran etexilate
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
26
States / cities
Hot Springs, Arkansas • Fremont, California • Moreno Valley, California + 21 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2016 · Synced Oct 1, 2026, 5:19 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study to Assess the Effect of Severe Renal Impairment on the Pharmacokinetics, as Well as Safety/Tolerability, of Ranolazine

NCT01675973
View directory record Official record
Conditions
Severe Renal Impairment
Interventions
RANEXA
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 6, 2012 · Synced Oct 1, 2026, 5:19 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Evacetrapib (LY2484595) in Participants With Severe Renal Impairment and in Healthy Participants

NCT01825889
View directory record Official record
Conditions
Cardiovascular Disease
Interventions
Evacetrapib
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
3
States / cities
Miami, Florida • Orlando, Florida • Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 9, 2018 · Synced Oct 1, 2026, 5:19 PM EDT
Completed Phase 2 Interventional Results available

Effect of Febuxostat on Renal Function in Patients With Gout and Moderate to Severe Renal Impairment

NCT01082640
View directory record Official record
Conditions
Renal Impairment
Interventions
Febuxostat, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
58
States / cities
Birmingham, Alabama • Peoria, Arizona • Sierra Vista, Arizona + 55 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2013 · Synced Oct 1, 2026, 5:19 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study of Eloralintide (LY3841136) in Participants With Different Levels of Liver Damage and in Participants With Healthy Livers.

NCT07401862
View directory record Official record
Conditions
Hepatic Insufficiency
Interventions
LY3841136
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 85 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
2
States / cities
Orlando, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 1, 2026, 5:19 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Drug Levels of Mezigdomide in Adult Participants With Renal Impairment

NCT06318676
View directory record Official record
Conditions
Renal Impairment
Interventions
Mezigdomide
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 82 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
3
States / cities
Miami Lakes, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jun 4, 2025 · Synced Oct 1, 2026, 5:19 PM EDT
Completed Phase 2 Interventional

Oxaliplatin With FOLFOX4 in Patients With Normal and Abnormal Renal Function

NCT00094965
View directory record Official record
Conditions
Gastrointestinal Cancer
Interventions
Oxaliplatin (SR96669)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 30, 2009 · Synced Oct 1, 2026, 5:19 PM EDT
Completed Phase 1 Interventional

A Study in Adults to Investigate the Impact of Mild, Moderate, and Severe Hepatic Impairment on Pharmacokinetics of Venglustat Compared to Participants With Normal Hepatic Function

NCT05718258
View directory record Official record
Conditions
Hepatic Function Abnormal
Interventions
Venglustat (GZ402671)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 79 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
5
States / cities
Rialto, California • Miami, Florida • Saint Paul, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2025 · Synced Oct 1, 2026, 5:19 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

PK Study of Intranasal RX0041-002 in Subjects With Severe Renal Impairment and Normal Renal Function

NCT02775955
View directory record Official record
Conditions
Healthy
Interventions
RX0041
Drug
Lead sponsor
Pharmaceutical Project Solutions, Inc.
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Berlin, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 6, 2018 · Synced Oct 1, 2026, 5:19 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single-dose Study to Investigate the Plasma PK of KW-6356 and Its Major Metabolite

NCT04190654
View directory record Official record
Conditions
Hepatic Impairment
Interventions
KW-6356
Drug
Lead sponsor
Kyowa Kirin, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
3
States / cities
Miami, Florida • Orlando, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 25, 2024 · Synced Oct 1, 2026, 5:19 PM EDT